Cargando…

Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Na(v)1.5 Channels

Eslicarbazepine acetate (ESL) is a dibenzazepine anticonvulsant approved as adjunctive treatment for partial-onset epileptic seizures. Following first pass hydrolysis of ESL, S-licarbazepine (S-Lic) represents around 95% of circulating active metabolites. S-Lic is the main enantiomer responsible for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leslie, Theresa K., Brückner, Lotte, Chawla, Sangeeta, Brackenbury, William J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567166/ https://www.ncbi.nlm.nih.gov/pubmed/33123007 http://dx.doi.org/10.3389/fphar.2020.555047

Ejemplares similares

Na(+) Channel β Subunits: Overachievers of the Ion Channel Family
por: Brackenbury, William J., et al.
Publicado: (2011)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Acidosis Differentially Modulates Inactivation in Na(V)1.2, Na(V)1.4, and Na(V)1.5 Channels
por: Vilin, Yury Y., et al.
Publicado: (2012)

Proton-dependent inhibition of the cardiac sodium channel Na(v)1.5 by ranolazine
por: Sokolov, S., et al.
Publicado: (2013)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study
por: Chaves, J., et al.
Publicado: (2017)

Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
por: Lawthom, Charlotte, et al.
Publicado: (2018)

Eslicarbazepine Acetate Modulates EEG Activity and Connectivity in Focal Epilepsy
por: Pellegrino, Giovanni, et al.
Publicado: (2018)

Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy
por: Tambucci, Renato, et al.
Publicado: (2016)

A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy
por: Singh, Rajinder P., et al.
Publicado: (2011)

Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate
por: Gidal, B. E., et al.
Publicado: (2018)

Transition from oxcarbazepine to eslicarbazepine acetate: A single center study
por: Mäkinen, Jussi, et al.
Publicado: (2017)

Voltage‐dependent activation of Rac1 by Na(v)1.5 channels promotes cell migration
por: Yang, Ming, et al.
Publicado: (2019)

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
por: Soares-da-Silva, Patrício, et al.
Publicado: (2015)

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies
por: Shorvon, S. D., et al.
Publicado: (2017)

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy
por: Saxena, S., et al.
Publicado: (2021)

MTSET modification of D4S6 cysteines stabilize the fast inactivated state of Na(v)1.5 sodium channels
por: O’Leary, Michael E., et al.
Publicado: (2015)

Na(v)1.5 regulates breast tumor growth and metastatic dissemination in vivo
por: Nelson, Michaela, et al.
Publicado: (2015)

Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies
por: Sperling, Michael R., et al.
Publicado: (2016)

Development of a stress induced validated UPLC-PDA method for the analysis of Eslicarbazepine acetate
por: Iram, Farah, et al.
Publicado: (2018)

Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli
por: Sales, Francisco, et al.
Publicado: (2020)

The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects
por: Hwang, Sejung, et al.
Publicado: (2022)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022)

Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer
por: Yang, Ming, et al.
Publicado: (2012)

Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast, Colorectal, and Prostate Cancer: A Systematic Review
por: Martin, Fabiola, et al.
Publicado: (2015)

Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes
por: Li, Jiamin, et al.
Publicado: (2021)

Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’
por: Öztiryaki, Ahmet H., et al.
Publicado: (2010)

Development and Validation of an RP-HPLC Method for Quantitative Estimation of Eslicarbazepine Acetate in Bulk Drug and Tablets
por: Singh, M., et al.
Publicado: (2013)

Adjunctive Treatment With Eslicarbazepine Acetate for Adults and Children With Focal-Onset Epilepsy: A Meta-Analysis
por: Fei, Yanqing, et al.
Publicado: (2022)

Evaluation of the Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Perampanel in Rats by Isotope-Dilution-UHPLC-MS/MS
por: Liu, Ping, et al.
Publicado: (2022)

Skeletal Muscle Na(+) Channel Disorders
por: Simkin, Dina, et al.
Publicado: (2011)

Lacosamide Inhibition of Na(V)1.7 Channels Depends on its Interaction With the Voltage Sensor Domain and the Channel Pore
por: Labau, Julie I. R., et al.
Publicado: (2021)

Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects
por: Falcão, Amílcar, et al.
Publicado: (2013)

Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
por: Galiana, Graciana L., et al.
Publicado: (2017)

Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures
por: Sunkaraneni, Soujanya, et al.
Publicado: (2018)

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
por: Costa, Raquel, et al.
Publicado: (2018)

Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
por: Mintz, Mark, et al.
Publicado: (2019)

Clinical utility of eslicarbazepine: current evidence
por: Zaccara, Gaetano, et al.
Publicado: (2015)

Calmodulin mutations affecting Gly114 impair binding to the Na(V)1.5 IQ-domain
por: Brohus, Malene, et al.
Publicado: (2023)

Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy
por: Lattanzi, Simona, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vlkj3ovhvs5piuiorlm4ujclul